Abstract
Buruli ulcer is a skin disease caused by Mycobacterium ulcerans that is spreading in tropical countries, with major public health and economic implications in West Africa. Multi-analyte profiling of serum proteins in patients and endemic controls revealed that Buruli ulcer disease down-regulates the circulating levels of a large array of inflammatory mediators, without impacting on the leukocyte composition of peripheral blood. Notably, several proteins contributing to acute phase reaction, lipid metabolism, coagulation and tissue remodelling were also impacted. Their down-regulation was selective and persisted after the elimination of bacteria with antibiotic therapy. It involved proteins with various functions and origins, suggesting that M. ulcerans infection causes global and chronic defects in the host's protein metabolism. Accordingly, patients had reduced levels of total serum proteins and blood urea, in the absence of signs of malnutrition, or functional failure of liver or kidney. Interestingly, slow healers had deeper metabolic and coagulation defects at the start of antibiotic therapy. In addition to providing novel insight into Buruli ulcer pathogenesis, our study therefore identifies a unique proteomic signature for this disease.
Highlights
Buruli ulcer disease (BUD) is a progressive ulceration of the skin that results from infection with Mycobacterium ulcerans [1,2,3]
Buruli ulcer is a skin disease caused by inoculation of Mycobacterium ulcerans bacteria, which is emerging in tropical countries
We found that Buruli ulcer disease induces a unique signature of serum protein suppression that outlasts the elimination of bacteria
Summary
Buruli ulcer disease (BUD) is a progressive ulceration of the skin that results from infection with Mycobacterium ulcerans [1,2,3]. The recommended treatment for BUD consists of streptomycin and rifampicin daily for eight weeks, with grafting of larger lesions [6,7,8]. This is effective at killing bacteria [9], 2–10% of individuals develop enlargement of lesions upon treatment [10]. To improve the current disease management practices and develop personalized treatment plans, it is crucial to better understand the pathophysiology of BUD and identify biological correlates of healing
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.